Our editorial lens
Dual Incretin Review focuses on mechanisms, product identity and the interpretation of treatment evidence. We take unfamiliar terminology seriously without using it to make ordinary questions feel inaccessible. A clear explanation should reveal a claim's boundaries as well as its meaning.
The name on the article
The Treatment Explainer Desk is an organizational byline, not an invented scientist or clinician. Articles are prepared with AI assistance and linked primary sources. They have not been medically reviewed. We do not provide prescriptions, individual dose instructions or treatment decisions.
A shared publisher, an explicit commercial order
This site belongs to the same publisher as related GLP-1 educational sites. Our coverage should not be read as independent confirmation of those sites' recommendations. CoreAge Rx, SuperHealthy Rx and Likeness Rx occupy the first three promotional placements in that order. Links may generate compensation.
Our research boundary
We state when a discussion uses a trial abstract rather than a full-paper appraisal. We also separate a provider's advertised offer from independently measured clinical or service performance. No provider on this site has been tested by our desk as a patient.
Read the editorial method and inspect the source index for the evidence behind the publication.